PALISADE CAPITAL MANAGEMENT, LP - NOVOCURE LTD ownership

NOVOCURE LTD's ticker is and the CUSIP is 67011XAB9. A total of 24 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
PALISADE CAPITAL MANAGEMENT, LP ownership history of NOVOCURE LTD
ValueSharesWeighting
Q3 2023$855,315
-0.7%
996,000
-0.4%
0.02%
+4.3%
Q2 2023$861,250
-1.2%
1,000,0000.0%0.02%
-4.2%
Q1 2023$871,681
-38.1%
1,000,000
-36.7%
0.02%
-40.0%
Q3 2022$1,408,000
+2.8%
1,580,0000.0%0.04%
+8.1%
Q2 2022$1,370,000
-4.7%
1,580,0000.0%0.04%
+12.1%
Q1 2022$1,438,000
+1.8%
1,580,000
+2.7%
0.03%
+13.8%
Q4 2021$1,412,0001,538,0000.03%
Other shareholders
NOVOCURE LTD shareholders Q3 2023
NameSharesValueWeighting ↓
STEELHEAD PARTNERS LLC 67,736,000$60,446,9294.40%
BRAIDWELL LP 131,834,000$117,582,7453.94%
DeepCurrents Investment Group LLC 38,391,000$34,368,1761.34%
SHENKMAN CAPITAL MANAGEMENT INC 16,861,000$14,946,8630.93%
Context Capital Management, LLC 12,489$11,1390.82%
WOLVERINE ASSET MANAGEMENT LLC 76,557,000$68,630,3670.71%
ABSOLUTE INVESTMENT ADVISERS, LLC 3,500,000$3,113,2500.47%
Aequim Alternative Investments LP 18,000,000$16,054,2000.44%
Ionic Capital Management LLC 2,000,000$1,781,5550.42%
Verition Fund Management LLC 27,771,000$24,768,9550.39%
View complete list of NOVOCURE LTD shareholders